Lupin partners with Celnova Pharma to distribute NaMuscla in Argentina and Colombia EP News Bureau Sep 27, 2024 NaMuscla (mexiletine) to be commercialised for the treatment of non-dystrophic myotonic disorders in adults
US FDA grants Lupin’s Mexiletine Orphan Drug Designation EP News Bureau Jun 8, 2020 Myotonic disorders are a group of heterogeneous, inherited, neuromuscular disorders characterized by a shared symptom called…
